Please login to the form below
BI 207127
This page shows the latest BI 207127 news and features for those working in and with pharma, biotech and healthcare.
Boehringer's faldaprevir set for rapid review in Europe
Meanwhile, faldaprevir is also in pivotal trials as part of an interferon-free regimen alongside non-nucleoside polymerase inhibitor BI 207127 and ribavirin.
Latest news
-
Boehringer says faldaprevir does well in Asian hepatitis C patients
Boehringer recently started pivotal trials of an interferon-free combination regimen for hepatitis C virus based on faldaprevir, polymerase inhibitor BI 207127 and ribavirin.
-
Boehringer launches online education portal for hepatitis C
The launch of the US-focused HepCRedefined.com site came on the day the pharma company moved its interferon-free hep C regimen, which combines faldaprevir and BI 207127, into phase
More from news
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Live Webinar: Navigating the Nuances of Europe's MedTech Industry
- Why project managers are key to creating quality content
- Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- A creative awakening – how pharma is bringing innovation to the patient journey
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
PMHub
M3 (EU)
M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
